HMC Capital Limited (ASX:HMC) has disclosed that director Christopher Roberts acquired 19,090 rights to acquire fully paid ordinary shares on 19 November 2026, granted at nil consideration under the company's Non-Executive Director Equity Plan in lieu of board fees for FY27.
Key Points
- Christopher Roberts received 19,090 rights to acquire fully paid ordinary shares on 19 November 2026
- The rights were granted at nil consideration in lieu of board fees for FY27 under the Non-Executive Director Equity Plan
- Roberts holds a direct interest of 21,786 fully paid ordinary shares and 19,090 rights following the change
- Indirect interests remain unchanged at 150,000 shares held through Romaxis Pty Ltd and 150,000 shares through Acemed Pty Ltd
Grant of Rights Under Non-Executive Director Equity Plan
According to the filing, the change of director's interest was lodged on 19 November 2026, with the previous notice dated 27 August 2026. The 19,090 rights to acquire fully paid ordinary shares were granted to Christopher Roberts in lieu of board fees for FY27 under HMC Capital's Non-Executive Director Equity Plan. The consideration for the acquisition was nil. No securities were disposed of as part of this transaction, and the filing confirmed the interests were not traded during a closed period requiring prior written clearance.
Christopher Roberts' Direct and Indirect Securities Holdings
Prior to the change, Roberts held a direct interest of 21,786 fully paid ordinary shares. Following the grant, his direct interest comprises 21,786 fully paid ordinary shares and 19,090 rights to acquire fully paid ordinary shares. His indirect interests remain unchanged. Romaxis Pty Ltd (ACN 126 199 924), as trustee for the Roblis Super Fund, of which Roberts is a beneficiary, holds 150,000 fully paid ordinary shares. Acemed Pty Ltd (ACN 078 477 193), as trustee for the MAXIS account, of which Roberts is also a beneficiary, holds a further 150,000 fully paid ordinary shares.
Nature of Indirect Interests Disclosed
The filing sets out the nature of Roberts' indirect interests in HMC Capital securities. Romaxis Pty Ltd holds its 150,000 shares in its capacity as trustee for the Roblis Super Fund Account, with Roberts disclosed as a beneficiary of that fund. Acemed Pty Ltd holds its 150,000 shares as trustee for the MAXIS Account, with Roberts also disclosed as a beneficiary. The filing states that Part 2, covering changes in director interests in contracts, was not applicable in relation to this notice, and no contract-related interests were reported.




Please wait processing your request...